Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
04 March 1998Website:
http://www.surmodics.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 17:00:00 GMTDividend
Analysts recommendations
Institutional Ownership
SRDX Latest News
NEW YORK , July 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc. (Nasdaq: SRDX ), relating to its proposed sale to GTCR LLC.
NEW YORK , May 29, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Surmodics, Inc. (NASDAQ: SRDX) and its board of directors concerning the proposed acquisition of the company by GTCR. Stockholders will receive $43.00 for each share of Surmodics stock that they hold.
MILWAUKEE , May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Surmodics (Nasdaq: SRDX) for possible breaches of fiduciary duty and other violations of law in its transaction with GTCR. Click here to learn how to join the https://www.ademilaw.com/case/surmodics-inc or call Guri Ademi toll-free at 866-264-3995.
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Surmodics (SRDX) demonstrates growth in the medical device sector with its fiscal second-quarter results. The company's bottom line surpasses the Zacks Consensus Estimate.
The key metrics for SurModics (SRDX) in the quarter ending March 2024 provide an indication of the company's performance, but it could be beneficial to compare these figures to Wall Street forecasts and the results from the same period last year.
SurModics (SRDX) reported earnings of $0.07 per share for the quarter, surpassing the Zacks Consensus Estimate of a loss of $0.36 per share. This is an improvement from a loss of $0.40 per share in the same quarter last year.
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust segmental revenues.
Surmodics, Inc (SRDX) Q1 2024 Earnings Call Transcript
- 1(current)
- 2
What type of business is Surmodics?
Surmodics, Inc. - a leading provider of medical devices and diagnostic technologies for healthcare system companies. The main focus is on cardiovascular diseases. The company was founded in 1979. The headquarters is located in the state of Minnesota. Surmodics, Inc. operates in two reporting business segments: the Medical Device Division - designs, develops, and manufactures interventional medical devices, primarily balloons and catheters for the treatment of peripheral artery diseases, urology, and others. The In Vitro Diagnostics Division - produces and sells components for diagnostic immunoassays, molecular tests, biomedical research.
What sector is Surmodics in?
Surmodics is in the Healthcare sector
What industry is Surmodics in?
Surmodics is in the Medical Devices industry
What country is Surmodics from?
Surmodics is headquartered in United States
When did Surmodics go public?
Surmodics initial public offering (IPO) was on 04 March 1998
What is Surmodics website?
https://www.surmodics.com
Is Surmodics in the S&P 500?
No, Surmodics is not included in the S&P 500 index
Is Surmodics in the NASDAQ 100?
No, Surmodics is not included in the NASDAQ 100 index
Is Surmodics in the Dow Jones?
No, Surmodics is not included in the Dow Jones index
When does Surmodics report earnings?
The next expected earnings date for Surmodics is 02 August 2024